The neutrophil‐to‐lymphocyte ratio at the start of the second course during atezolizumab plus bevacizumab therapy predicts therapeutic efficacy in patients with advanced hepatocellular carcinoma: A multicenter analysis
Sho Matoya, Takanori Suzuki, K. Matsuura, Yuta Suzuki +18 more

